Rapport Therapeutics, Inc. (RAPP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$23.72-8.52%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RAPP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 148.7 | 94.8 | 60.9 | 28.0 | — |
| Operating Income | (167.6) | (125.1) | (83.1) | (36.2) | — |
| Earnings from Continuing Operations | |||||
| Interest & Investment Income | 17.1 | 13.6 | 12.1 | 2.5 | — |
| Other Non-Operating Income / Expenses | 17.1 | 13.6 | 4.7 | 1.4 | — |
| Asset Writedown | — | — | — | 0.0 | — |
| EBT, Incl. Unusual Items | — | — | (78.3) | (34.8) | — |
| Income Tax Expense | — | — | — | 0.0 | — |
| Net Income | |||||
| Net Income | (150.5) | (111.5) | (78.3) | (34.8) | — |
| Per Share | |||||
| Basic EPS | (3.15) | (2.86) | (3.78) | (23.10) | — |
| Diluted EPS | (3.15) | (2.86) | (3.78) | (23.10) | — |
| Basic Weighted Avg Shares | 47.8 | 38.9 | 20.7 | 1.5 | — |
| Diluted Weighted Avg Shares | 47.8 | 38.9 | 20.7 | 1.5 | — |
| Supplemental | |||||
| EBITDA | — | (124.1) | (82.2) | (36.1) | — |
| EBIT | (167.6) | (125.1) | (83.1) | (36.2) | — |
| Effective Tax Rate | — | — | — | -0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.